{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:53:23Z","timestamp":1789502003608,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The superiority of total body irradiation (TBI)\u2013based vs chemotherapy conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukemia (ALL) has been established in the international, prospective phase-3 FORUM study, randomizing 417 patients aged 4-18 years in complete remission (CR), who received allo-HSCT from HLA-matched sibling or unrelated donors. Because of the unavailability of TBI in some regions and to accommodate individual contraindications, this study reports the prespecified comparison of outcomes of patients receiving busulfan (BU)\u2013 or treosulfan (TREO)\u2013based regimens from 2013 to 2018. Overall, 180 and 128 patients received BU\/thiotepa (THIO)\/fludarabine (FLU) or TREO\/THIO\/FLU, respectively. Data were analyzed as of February 2023, with a median follow-up of 4.2 years (range, 0.3-9.1). 3-year overall survival was 0.71 (BU, 95% confidence interval [0.64-0.77]) and 0.72 (TREO, [0.63-0.79]) and 3-year event-free survival was 0.60 (BU, [0.53-0.67]) and 0.55 (TREO, [0.46-0.63]). The 3-year cumulative incidence of relapse (BU, 0.31 [0.25-0.38]; TREO, 0.36 [0.27-0.44]); and nonrelapse mortality (BU, 0.08 [0.05-0.13]; TREO, 0.09 [0.05-0.15]) were comparable. One case of fatal veno-occlusive disease occurred in each group. No significant differences in acute and chronic graft-versus-host disease (GVHD) or 3-year GVHD-free and relapse-free survival (BU, 0.48 [0.41-0.55]; TREO, 0.45 [0.37-0.54]) were recorded. Outcomes for patients in first and second CR were similar irrespective of the regimen. In conclusion, BU\/THIO\/FLU or TREO\/THIO\/FLU regimens can be an alternative to TBI for patients with ALL aged &amp;gt;4 years with contraindications or lack of access to TBI. This trial was registered at www.ClinicalTrials.gov as #NCT01949129.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014548","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:53:27Z","timestamp":1732730007000},"page":"741-751","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Kalwak","sequence":"first","affiliation":[{"name":"1Department of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1241-5137","authenticated-orcid":false,"given":"Laura M.","family":"Moser","sequence":"additional","affiliation":[{"name":"2Division for Stem Cell Transplantation and Immunology, Department of Pediatrics, Goethe University Frankfurt, University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"P\u00f6tschger","sequence":"additional","affiliation":[{"name":"3St. Anna Children\u2019s Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"Peter","family":"Bader","sequence":"additional","affiliation":[{"name":"2Division for Stem Cell Transplantation and Immunology, Department of Pediatrics, Goethe University Frankfurt, University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-7286","authenticated-orcid":false,"given":"Katharina","family":"Kleinschmidt","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Hematology, Oncology, and Stem Cell Transplantation, University Children\u2019s Hospital Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-0628","authenticated-orcid":false,"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[{"name":"5Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-0793","authenticated-orcid":false,"given":"Jean-Hugues","family":"Dalle","sequence":"additional","affiliation":[{"name":"6Pediatric Hematology and Immunology Department, Robert Debr\u00e9 Hospital, Groupe Hospitalo-Universitaire Assistance Publique H\u00f4pitaux de Paris Nord, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif","family":"Yesilipek","sequence":"additional","affiliation":[{"name":"7Medical Park Antalya Hospital, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-0610","authenticated-orcid":false,"given":"Adriana","family":"Balduzzi","sequence":"additional","affiliation":[{"name":"8School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy"},{"name":"9Pediatric Hematopoietic Stem Cell Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Krivan","sequence":"additional","affiliation":[{"name":"10Pediatric Hematology and Stem Cell Transplantation Department, National Institute of Hematology and Infectious Diseases, Central Hospital of Southern Pest, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenios","family":"Goussetis","sequence":"additional","affiliation":[{"name":"11Stem Cell Transplant Unit, Agia Sofia Children's Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Staciuk","sequence":"additional","affiliation":[{"name":"12Hospital de Pediatr\u00eda \u201cProf. Dr Juan P. Garrahan,\u201d Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-2886","authenticated-orcid":false,"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[{"name":"13Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-5123","authenticated-orcid":false,"given":"Herbert","family":"Pichler","sequence":"additional","affiliation":[{"name":"3St. Anna Children\u2019s Cancer Research Institute, Vienna, Austria"},{"name":"14Department of Pediatric Hematology and Oncology, St. Anna Children\u2019s Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Svec","sequence":"additional","affiliation":[{"name":"15Department of Pediatric Hematology and Oncology, National Institute of Children\u2019s Diseases, Comenius University, Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Gabriel","sequence":"additional","affiliation":[{"name":"16The Children\u2019s Hospital at Westmead, Sidney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-1186","authenticated-orcid":false,"given":"Tayfun","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[{"name":"17Division of Hematology\/Oncology\/Immunology, Gene Therapy, and Stem Cell Transplantation, University Children's Hospital Zurich, Eleonore Foundation and Children\u2019s Research Center, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Bilic","sequence":"additional","affiliation":[{"name":"18Division for Hematology and Oncology, Department of Pediatrics Zagreb, University Hospital Center, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-4501","authenticated-orcid":false,"given":"Jochen","family":"Buechner","sequence":"additional","affiliation":[{"name":"19Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Renard","sequence":"additional","affiliation":[{"name":"20Department of Paediatric Oncology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-0135","authenticated-orcid":false,"given":"Kim","family":"Vettenranta","sequence":"additional","affiliation":[{"name":"21University of Helsinki and the Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Ifversen","sequence":"additional","affiliation":[{"name":"22Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8086-296X","authenticated-orcid":false,"given":"Cristina","family":"Diaz-de-Heredia","sequence":"additional","affiliation":[{"name":"23Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Stein","sequence":"additional","affiliation":[{"name":"24Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine Tel Aviv University, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Toporski","sequence":"additional","affiliation":[{"name":"25Department Cell Therapy and Allogeneic Stem Cell Transplant, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0192-3080","authenticated-orcid":false,"given":"Marc","family":"Bierings","sequence":"additional","affiliation":[{"name":"26Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-8515","authenticated-orcid":false,"given":"Christina","family":"Peters","sequence":"additional","affiliation":[{"name":"3St. Anna Children\u2019s Cancer Research Institute, Vienna, Austria"},{"name":"14Department of Pediatric Hematology and Oncology, St. Anna Children\u2019s Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[{"name":"27CANSEARCH Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland"},{"name":"28Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"29Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Ges\u00f9, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"4","key":"2025032418271989700_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025032418271989700_bib2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1182\/bloodadvances.2023010591","article-title":"Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study","volume":"8","author":"Bader","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2025032418271989700_bib3","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/bloodadvances.2018016956","article-title":"Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine","volume":"2","author":"Harris","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2025032418271989700_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41409-023-02135-9","article-title":"Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial","volume":"59","author":"Sykora","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2025032418271989700_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"2","key":"2025032418271989700_bib6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"2","key":"2025032418271989700_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2025032418271989700_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00277-014-2196-8","article-title":"Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia","volume":"94","author":"Boztug","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2025032418271989700_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbmt.2016.11.001","article-title":"Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results","volume":"23","author":"Kebriaei","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025032418271989700_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41409-020-0854-0","article-title":"Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?\u2014a multicenter EBMT-PDWP study","volume":"55","author":"Willasch","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2025032418271989700_bib11","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41409-020-0869-6","article-title":"Treosulfan\u2013fludarabine\u2013thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies","volume":"55","author":"Kalwak","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2025032418271989700_bib12","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1182\/blood-2022-166048","article-title":"Long-term data confirm the superiority of total body irradiation-containing conditioning regimen in comparison to a chemotherapy-based preparation in children with acute lymphoblastic leukemia above the age of 4 years given an unmanipulated allograft. Results of the Forum Randomized Clinical Trial","volume":"140","author":"Locatelli","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025032418271989700_bib13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2014.03.028","article-title":"Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation","volume":"20","author":"Shah","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2025032418271989700_bib14","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv"},{"issue":"21","key":"2025032418271989700_bib15","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","article-title":"Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group","volume":"31","author":"Eckert","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"2025032418271989700_bib16","doi-asserted-by":"crossref","first-page":"101136","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev"},{"issue":"4","key":"2025032418271989700_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3892\/mco.2016.765","article-title":"Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients","volume":"4","author":"Dai","year":"2016","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"2025032418271989700_bib18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1200\/JCO.1991.9.7.1224","article-title":"Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation","volume":"9","author":"Nevill","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025032418271989700_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"De Lima","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2025032418271989700_bib20","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.bbmt.2015.08.023","article-title":"Transplant outcomes for children with T cell acute lymphoblastic leukemia in second remission: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Burke","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2025032418271989700_bib21","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.bbmt.2017.08.036","article-title":"Outcome analysis of pediatric patients with acute lymphoblastic leukemia treated with total body irradiation\u2013free allogeneic hematopoietic stem cell transplantation: comparison of patients with and without central nervous system involvement","volume":"23","author":"Hamidieh","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2025032418271989700_bib22","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.bbmt.2018.03.001","article-title":"Current allogeneic hematopoietic stem cell transplantation for pediatric acute lymphocytic leukemia: success, failure and future perspectives\u2014a single-center experience, 2008 to 2016","volume":"24","author":"Yanir","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025032418271989700_bib23","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.bbmt.2017.04.015","article-title":"Factors associated with long-term risk of relapse after unrelated cord blood transplantation in children with acute lymphoblastic leukemia in remission","volume":"23","author":"Page","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2025032418271989700_bib24","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"issue":"17","key":"2025032418271989700_bib25","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025032418271989700_bib26","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","article-title":"Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial","volume":"109","author":"Pennesi","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"2025032418271989700_bib27","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/S2352-3026(23)00091-1","article-title":"Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia","volume":"10","author":"Ghara","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"2025032418271989700_bib28","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.22.02345","article-title":"CAR T-cells for cure in pediatric B-ALL","volume":"41","author":"Gardner","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2025032418271989700_bib29","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.2018874115","article-title":"Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation","volume":"133","author":"Baker","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2025032418271989700_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11912-018-0719-5","article-title":"Long-term effects of myeloablative allogeneic hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia","volume":"20","author":"Lawitschka","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"2025032418271989700_bib31","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/s41409-020-0806-8","article-title":"Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospec","volume":"55","author":"Saglio","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2025032418271989700_bib32","doi-asserted-by":"crossref","first-page":"773895","DOI":"10.3389\/fped.2021.773895","article-title":"Late effects after haematopoietic stem cell transplantation in ALL, long-term follow-up and transition: a step into adult life","volume":"9","author":"Diesch-Furlanetto","year":"2021","journal-title":"Front Pediatr"},{"key":"2025032418271989700_bib33","doi-asserted-by":"crossref","first-page":"807992","DOI":"10.3389\/fped.2022.807992","article-title":"Acute lymphoblastic leukaemia in the youngest: haematopoietic stem cell transplantation and beyond","volume":"10","author":"Balduzzi","year":"2022","journal-title":"Front Pediatr"},{"issue":"35","key":"2025032418271989700_bib34","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1200\/JCO.2014.56.2223","article-title":"Cognitive outcome after pediatric stem-cell transplantation: impact of age and total-body irradiation","volume":"32","author":"Willard","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/741\/2355645\/blooda_adv-2024-014548-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/741\/2355645\/blooda_adv-2024-014548-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:12:43Z","timestamp":1742847163000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/741\/526315\/Comparable-outcomes-after-busulfan-or-treosulfan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014548","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}